NCT03330847 2026-03-10
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
Phase 2 Active not recruiting
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca